Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells.

doi:10.1016/j.ejphar.2024.177161

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells.

European journal of pharmacology - 15 Jan 2025

Lipreri da Silva Jean Carlos, Lima Keli, Ede Benjamin, Lazarini Mariana, Vicari Hugo Passos, Nogueira Frederico Lisboa, Clayton Natasha S, Pinnell Katy, Silva Wellington Fernandes da, Velloso Elvira Deolinda Rodrigues Pereira, Bendit Israel, Costa-Lotufo Leticia Veras, Rego Eduardo Magalhães, Ridley Anne J, Machado-Neto João Agostinho

Abstract excerpt

Ezrin (EZR) is an actin-associated protein that is often upregulated in cancers. Here we investigate the role of EZR in acute lymphoblastic leukemia (ALL) and explore the therapeutic potential of a pharmacological EZR inhibitor, NSC305787. ALL patient cohorts exhibit significantly elevated EZR mRNA levels, indicating its association with the malignant phenotype. Notably, EZR expression does not impact survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis

Share to Cell Adhesion

Share to Cell Survival

Share to Cytoskeletal Proteins

Share to Neoplasm Invasiveness

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Quinolines

Source

Open in PubMed

Identifiers

PMID: 39615869
DOI: 10.1016/j.ejphar.2024.177161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells.PMID 39615869Read ↗

Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemiaSemantic proximity Read ↗

Ezrin Inhibition Up-regulates Stress Response Gene ExpressionSemantic proximity Read ↗

Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A ReviewSemantic proximity Read ↗

Pathophysiological Roles of Actin-Binding Scaffold Protein, EzrinSemantic proximity Read ↗

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemiaSemantic proximity Read ↗

The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatmentSemantic proximity Read ↗

The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

The ezrin protein family: membrane-cytoskeleton interactions and disease associationsSemantic proximity Read ↗

EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress.Semantic proximity Read ↗

Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells in vitroSemantic proximity Read ↗

Integrated in silico and in vitro approaches identify a HSP90 drug vulnerability axis in t(7;12) infant leukemia stem-like cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.